FGFR3 and plasma cell myeloma: Although the subprotocol of the phase 2 MATCH basket study looked to treat only FGFR3-amplified tumors with AZD4547, no multiple myeloma patients were ultimately enrolled and the subprotocol failed to meet its goal of a 16% response rate among other cancers treated (93).